35 results about "Clostridial infection" patented technology

The invention includes a formulation comprising: (i) a therapeutically effective amount of at least one antibiotic; and (ii) a therapeutically effective amount of at least one probiotic material. The formulation is prepared in a dosage form for delivery to the gastrointestinal tract. The invention further includes a method of preventing or minimizing the proliferation of Clostridium difficile in the gastrointestinal tract of a mammal undergoing an antibiotic therapy comprising by administration of the formulation of the invention for the duration of the antibiotic therapy; methods of preventing or minimizing the occurrence of antibiotic-associated diarrhea in a mammal undergoing an antibiotic therapy that includes administering the formulation; and methods of preventing or minimizing the occurrence of antibiotic-associated colitis or pseudomembranous colitis in a patient undergoing an antibiotic therapy that includes administering the formulation.Also included are methods of reducing or preventing a failure of treatment for an antibiotic-treatable infection in a patient comprising orally administering the formulation.Described by the invention are formulations for the treatment of a C. difficile infection comprising: (i) a therapeutically effective amount of at least one antibiotic; and (ii) a therapeutically effective amount of at least one probiotic material. The antibiotic includes a non-systemic gram negative antibiotic (such as, for example, fodaximicin) and formulation is prepared in a dosage form for delivery to the gastrointestinal tract.Also included are methods of treatment of a C. difficile infection in mammal that include administering to the digestive tract of the mammal the above described formulation. Such methods provide that the likelihood that the mammal shall experience a reoccurrence of the C. difficile infection is 70% or less.

This invention relates to prophylactic and / or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its microbial content to the distal small intestine and / or colon in high quantities and density, which is a “normalized” approach to repopulate the colonic flora as a method of prevention and / or treatment of, for example, Clostridium difficile colitis.

Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and / or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.

The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.

Embodiments of the invention include methods and / or compositions for analysis of samples for C. difficile infection to determine whether or not an individual is at risk for having recurrent C. difficile infection or a CDI misdiagnosis. Methods include characterization of microflora composition from the gut, wherein alterations of the microflora gut composition are indicative of recurrence of infection. Methods include analysis of nucleic acids from the gut, such as 16S rRNA as being identifying of a particular bacteria in the analysis of bacterial populations of the gut.

This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and / or colonic treatments, and methods for making, storing and using them, including storage, including long term storage, at ambient temperature. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disordor, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C.difficile infection.

The invention discloses a tetanus toxin-resistant neutralizing antibody as well as preparation and application thereof. The antibody can be used for preventing, treating and diagnosing tetanus infection and / or treating one or more symptoms mediated by clostridium tetani infection. The invention further provides a method for producing an antibody capable of combining with tetanus toxin immunologically specifically.

Provided herein are analog and derivative compounds of inositol hexakisphosphate effective to treat a Clostridium difficile infection and to neutralize the bacterial toxins produced by the same. In addition, methods of treating the C. difficile infection and for neutralizing its toxins with the compounds are provided.

The present invention provides novel human-derived monoclonal antibodies specifically binding to toxins produced by Clostridium difficile (toxin A and toxin B), respectively, and having excellent neutralizing activity, and antigen-binding fragments thereof. The present invention also provides a pharmaceutical composition for the treatment of Clostridium difficile infection comprising any of the antibodies or antigen-binding fragments thereof.

Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of clofazimine and / or a clofazimine analogue. Pharmaceutical compositions comprising clofazimine and / or an analogue(s) thereof, and optionally one or more additional therapeutic agents, are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.

The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of a pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.

The invention provides methods for treating or inhibiting infection by Clostridium difficile in a subject in need of such treatment, comprising administering an effective amount of a compound binding to a CD3299 riboswitch, as well as assays for identifying compounds useful in such treatment, and the use of particular compounds in such treatment.

Described are immunogenic proteins against Clostridium difficile. Also described are compositions comprising the immunogenic proteins. Further described are methods of preventing or treating a Clostridium difficile infection in a subject in need thereof.

The invention belongs to the technical field of medicines, and particularly relates to application of fresh ginger heart fire-removing decoction in curing diarrhoea caused by clostridium difficile infection. According to the application of the fresh ginger heart fire-removing decoction in curing diarrhoea caused by clostridium difficile infection, based on the existing pharmacological activity ofthe fresh ginger heart fire-removing decoction, through a large number of experiments and in-depth studies, new clinical efficacy of the fresh ginger heart fire-removing decoction is screened, and experimental results show that the fresh ginger heart fire-removing decoction has the application in curing diarrhoea caused by clostridium difficile infection.

The invention provides an application of a compound as shown in the formula A to preparation of a medicine for restraining clostridium difficile thalli and / or restraining germination of clostridium difficile spores. R1 and R2 are independently selected from C1-3 alkyl group, C2-3 alkenyl and C2-3 alkynyl. Experiment proves that the compound as shown in the formula A, particularly magnolol and honokiol can notably restrain activity of clostridium difficile, can notably restrain germination of clostridium difficile spores, and has good application prospects for preparation of the medicine for preventing and / or treating clostridium difficile infection diseases, recurrence of clostridium difficile infection diseases, and complications of clostridium difficile infection diseases.

The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.

Clostridium difficile infection is the leading cause of hospital acquired antibiotic-associated diarrhea in the US (Bartlett, in 2006). The increased prevalence of circulating C. difficile strains poses a significant health threat to US health care facilities. Strains expressing the toxin C. difficile Transferase (CDT), in addition to Toxins A and B (TcdA and TcdB), are more virulent and are associated with higher mortality rates (Bacci et al., 2011). We recently identified a protective role for eosinophils against C. difficile pathogenesis (Buonomo et al., 2016). We have also defined CDT's ability to increase host inflammation and suppress protective eosinophils through a TLR2 dependent mechanism (Cowardin et al., 2016). How CDT promotes virulence and eosinophil suppression via TLR2 is still under investigation. We employed a genome-wide microarray approach to reveal divergent transcriptional profiles between protected (TLR2− / −) and unprotected (WT) mice infected with either CDT expressing or CDT mutant strains of C. difficile. This work revealed novel host mediated TLR2-dependent inflammatory pathways to CDT. We provide an unbiased framework for understanding the host immune response to the binary toxin CDT produced by C. difficile and how TLR2 signaling enhances virulence.

The present invention relates to methods of preventing Clostridium difficile infection (COI) in a human subject who is at high risk of developing this infection, comprising administering to the subject an effective amount of the compounds described herein. In some embodiments, the subject is further receiving concomitant antibiotic therapy to prevent and / or treat an infection other than Clostridium. In some embodiments, the subject previously was treated for a Clostridium infection. In some embodiments, the compound of formula I prevents the Clostridium infection.

The invention provides a protein interacted with clostridium difficile cytotoxin B. The protein is chondroitin sulfate protein polysaccharide CSPG4 or a polypeptide formed by 640 amino acids at the N end of the CSPG4 protein. The invention firstly finds that the CSPG4 has the function of a clostridium difficile cytotoxin B cell receptor, the toxicity of the clostridium difficile cytotoxin B can be obviously reduced by restraining the expression or the function of the CSPG4, and a new thought is provided for treating the clostridium difficile infection.

The present invention is directed to the use of nifuratel, or a physiologically acceptable salt thereof, to treat infections caused by bacteria species of the genus Clostridium. The invention is further directed to the use of nifuratel to treat Clostridium difficile infection (CDI) and in particular Clostridium difficile associated diarrhoea (CDAD).

Methods are described for identifying CDI patients as well as CDI patients at risk for recurrence. Embodiments include: (1) flow cytometry of circulating peripheral blood mononuclear cells (PBMC) to phenotype for the less efficient immunoglobulin response to bacterial toxins and surface antigens that characterizes patients who will become recurrent; (2) stratification by means of complete blood count (CBC) using a Coulter counter to detect the differences in lower angle light scatter (LAL), which has a larger range in the recurrent population; and (3) stratification by means of complete blood count (CBC) using a Coulter counter to detect the lower axial light loss (AL2) exhibited in recurrent patients.

The invention discloses the application of thiopeptidecycline in the preparation of medicines for treating Clostridium difficile infectious diseases and its complications. Thiopeptidecycline has significant activity against Clostridium difficile and its drug-resistant strains, and has important clinical application value. In vivo experiments have verified that the thiopeptidecycline does not enter the blood circulation after oral administration. In view of the characteristics of intestinal administration, the present invention also provides an oral preparation of the thiopeptidecycline containing a safe and effective dose and a preparation method thereof.

Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a synergistic combination of clofazimine and metronidazole. Pharmaceutical compositions comprising clofazimine and metronidazole are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.